Toxicology & Safety Profiling: Assess offtarget sympathomimetic effects, renal and muscle toxicity risks, and doselimiting tolerability in animal studies PubMed
As obesity reaches epidemic proportions globally, recognizing the long-term health benefits and cost savings associated with successful weight management is vital
DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD PDF Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035 USD 72.29 BN MARKET SIZE, 2035 BIOSIMILARS MARKET SIZE, SHARE & GROWTH SNAPSHOT Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The global biosimilars market is projected to grow from USD 35.04 billion in 2025 to USD 72.29 billion by 2035, at a CAGR of 7.5% during the forecast period
At 6 months, 68% had returned to weekly dosing, citing no perceived benefit and increased hassle